

IN THE CLAIMS

1. (Currently Amended) ~~Vaccine~~ A vaccine adjuvant adjuvants characterized by a Proteoliposomal structure or a derivatives derivative thereof having the capability of it capable to induce a CTL response.
2. (Currently Amended) ~~Vaccine adjuvants like in~~ The vaccine adjuvant of claim 1, characterized by a bacterial origin.
3. (Currently Amended) ~~Vaccine adjuvants like in~~ The vaccine adjuvant of claim 2, ~~that come from~~ comprising a Neisseria or Salmonella genus.
4. (Currently Amended) ~~Vaccine adjuvants like in~~ The vaccine adjuvant of claim 1, which ~~express~~ expresses the antigens at least one antigen of interest from a strain modified by genetic ~~engeneering~~ engineering.
5. (Currently Amended) ~~Vaccine~~ A vaccine formulation comprising the adjuvant characterized by including the adjuvants described from of claim 1 to 4, further comprising at least one or more antigens antigen of interest as well as suitable and an excipient.

6. (Currently Amended) Vaccine The vaccine formulation of like in claim 5,  
characterized by the insertion of the antigen (s) of interest in the lipidic bilayer of  
the Proteoliposomes or a derivative thereof being also present in its derivatives.

7. (Currently Amended) Vaccine The vaccine formulation like in of claim 5,  
characterized by the conjugation of the antigen (s) of interest to the  
Proteoliposomes or a derivative thereof being also present in its derivatives.

8. (Currently Amended) The vaccine Vaccine formulation of like in claim 5,  
characterized by the co-administration of the antigen (s) of interest with the  
Proteoliposomes or its derivatives derivative thereof.

9. (Currently Amended) The vaccine Vaccine formulation like in of claim 5,  
characterized by a concentration rank of the Proteoliposomes or its derivatives a  
derivative thereof between 1 and 50 µg, particularly between 5 and 25 µg.

10. (Currently Amended) The vaccine Vaccine formulation like in of claim 5,  
characterized by a concentration rank of the antigen (s) of interest from 0.1 to  
20% of the mass of the Proteoliposomes or its derivatives a derivative thereof,  
particularly from 0.5 to 10%.

11. (Currently Amended) The vaccine Vaccine formulation of like in claims claim  
5 to 10, which said formulation being in a form to be administered by at least one  
of the following means, intramuscularly, intraperitonealy, intradermically,  
subcutaneously, or mucosaly by oral/feed, or nasal/respiratory routes and or by  
genitourinary tract.

12. (Currently Amended) The use of vaccine formulation like in claims 5 to of  
claim 10, comprising administering the formulation to a mammal in need of  
treatment to protect said mammal mammals susceptible to infections or and to  
treat tumoral deseases diseases.

13. (Currently Amended) An immunization Immunization schedule comprising  
administering using the vaccine formulation like in claims of claim 5 to 10,  
characterized by the application administering of three doses of said formulation  
as a maximum to achieve a profilactic prophylactic effect and five doses as  
maximum to achieve a therapeutic effect.

14. (New) An immunization schedule comprising administering the formulation  
of claim 10, and further characterized by administering 5 doses of said  
formulation as a maximum to achieve a therapeutic effect.

15. (New) The vaccine formulation of claim 9, wherein the concentration is between 5 and 25 µg.

16. (New) The vaccine formulation of claim 10, wherein the concentration is between 0.5 to 10% of said mass.

17. (New) A method for treating a mammal for tumoral diseases comprising:

- (a) providing a formulation comprising a vaccine adjuvant comprising a Proteoliposomes structure or a derivative thereof.
- (b) administering the formulation of step (a) to a mammal in need of said treatment.

18. (New) The method of claim 17, wherein the formulation comprises at least one antigen of interest, and wherein the concentration of the antigen of interest is from 0.1 to 20% by weight of the mass of the Proteoliposomes or in a derivative thereof.